ビスダイン
- 関
- verteporfin
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/09/11 18:59:11」(JST)
[Wiki en表示]
Verteporfin
|
| Systematic (IUPAC) name |
|
3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
|
| Clinical data |
| Trade names |
Visudyne |
| AHFS/Drugs.com |
Monograph |
| MedlinePlus |
a607060 |
Pregnancy
category |
- US: C (Risk not ruled out)
|
Routes of
administration |
Intravenous |
| Legal status |
| Legal status |
|
| Identifiers |
| CAS Number |
129497-78-5 Y |
| ATC code |
S01LA01 (WHO) |
| PubChem |
CID 5362420 |
| DrugBank |
DB00460 Y |
| ChemSpider |
21106402 Y |
| UNII |
0X9PA28K43 Y |
| KEGG |
D01162 Y |
| ChEBI |
CHEBI:60775 Y |
| ChEMBL |
CHEMBL2218885 N |
| Chemical data |
| Formula |
C41H42N4O8 |
| Molar mass |
718.794 g/mol |
SMILES
-
COC(=O)[C@@H]2C(=C\C=C3\c1cc6nc(cc5nc(cc4nc(cc(n1)[C@]23C)C(/C)=C4/CCC(=O)OC)c(CCC(O)=O)c5C)C(/C=C)=C6/C)/C(=O)OC
|
InChI
-
InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,33-18-,34-17-,35-19-/t38-,41+/m0/s1 Y
-
Key:ZCQHFRFEJXRZDF-YWANUUMDSA-N Y
|
| NY (what is this?) (verify) |
Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 689 nm[1] in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.[2][3]
Verteporfin is also used off-label for the treatment of central serous retinopathy.[4]
Contents
- 1 Administration
- 2 Contraindications
- 3 Side effects
- 4 Interactions
- 5 References
- 6 External links
Administration
Verteporfin is given intravenously, 15 minutes before laser treatment.[2]
Contraindications
Porphyria.[2]
Side effects
Most common side effects are blurred vision, headache, and local effects at the injection site. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin.[2]
Interactions
Verteporfin is known to interact with the herbal remedy feverfew (Tanacetum parthenium), the latter of which seems to act as an antagonist to verteporfin for unknown reasons. Taking the two substances simultaneously is inadvisable.[5]
Verteporfin has no influence on the liver enzyme CYP3A4, which metabolises many pharmaceutical drugs.[2]
References
- ^ "Visudyne package insert" (PDF).
- ^ a b c d e Verteporfin Monograph
- ^ Scott, L. J.; Goa, K. L. (2000). "Verteporfin". Drugs & aging. 16 (2): 139–146; discussion 146–8. doi:10.2165/00002512-200016020-00005. PMID 10755329.
- ^ Adelman, R.; Adelman, R. A. (2013). "Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy". Clinical Ophthalmology. 7: 1867–1875. doi:10.2147/OPTH.S32177. PMC 3788817. PMID 24092965.
- ^ "Feverfew and Verteporfin Interactions". Retrieved 14 April 2015.
External links
- Novartis website for Visudyne
- Research into using verteporfin to treat pancreatic cancer
|
Ophthalmologicals: ocular vascular disorder agents (S01L)
|
|
| Antineovascularisation agents |
- Aflibercept
- Anecortave
- Bevacizumab
- Pegaptanib
- Ranibizumab
- Verteporfin
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Activated Hippo/Yes-Associated Protein Pathway Promotes Cell Proliferation and Anti-apoptosis in Endometrial Stromal Cells of Endometriosis.
- Song Y1, Fu J1, Zhou M1, Xiao L1, Feng X1, Chen H1, Huang W1.
- The Journal of clinical endocrinology and metabolism.J Clin Endocrinol Metab.2016 Mar 15:jc20161120. [Epub ahead of print]
- CONTEXT: The imbalance in cell proliferation and apoptosis is considered an important role in the pathogenesis of endometriosis, but the exact mechanisms remains unclear. A newly established signaling pathway-Hippo/Yes-associated protein (YAP) pathway plays a critical role in the proliferation and a
- PMID 26977530
- Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
- Smretschnig E1,2, Hagen S1,2, Glittenberg C1,2, Ristl R3, Krebs I1,2, Binder S1,2,4, Ansari-Shahrezaei S1,2,4,5.
- Eye (London, England).Eye (Lond).2016 Mar 11. doi: 10.1038/eye.2016.41. [Epub ahead of print]
- PurposeTo evaluate the results of indocyanine green angiography (ICGA)-guided verteporfin photodynamic therapy (PDT) with half-fluence rate combined with intravitreal application of anti-VEGF in treating choroidal neovascularization (CNV) in chronic central serous chorioretinopathy (CSCR).Patients a
- PMID 26965012
- Optimized Rhodamine B labeled mesoporous silica nanoparticles as fluorescent scaffolds for the immobilization of photosensitizers: a theranostic platform for optical imaging and photodynamic therapy.
- Martins Estevão B1, Miletto I2, Marchese L2, Gianotti E2.
- Physical chemistry chemical physics : PCCP.Phys Chem Chem Phys.2016 Mar 11. [Epub ahead of print]
- A highly efficient bifunctional mesoporous silica nanodevice coupling optical imaging with photodynamic therapy (PDT) was successfully prepared by using Rhodamine B as a contrast agent and verteporfin as a photosensitizer. The precise localization and high dispersion of the contrast agent in the nan
- PMID 26967375
Japanese Journal
- 尾花 明
- 日本レーザー医学会誌 = The Journal of Japan Society for Laser Medicine 28(2), 176-181, 2007-07-15
- NAID 10019728854
- ベルテポルフィン(ビスダイン^【○!R】)の基礎および臨床
- 川崎 輝美
- 眼薬理 = Japanese journal of ocular pharmacology 19(1), 20-25, 2005-06-24
- NAID 10016567473
Related Links
- 加齢黄斑変性（PDT）にビスダインをご利用になられている患者さんと医療関係者にビスダインの適正使用の情報を掲載しております。スイスの製薬会社ノバルティスファーマ株式会社のサイトです。
- Visudyne (verteporfin for injection) is a light-activated drug used in photodynamic therapy. Visudyne offers an anatomical treatment that occludes mature vessels that may be expressing less or no VEGF. It works to effect vaso ...
Related Pictures
★リンクテーブル★
[★]
- 英
- verteporfin
- 商
- ビスダイン Visudyne
[★]
ベルテ・ルフィン
- 関
- Visudyne